Prof. Martin Reck (German Center for Lung Research, Germany) cited recent data from landmark trials to promote immunotherapy combined with other treatment options. “We have suggestions of multiple interactions and potential synergies,” said Prof. Reck at a mini-symposium on the Future of IO. These include immunotherapy plus chemotherapy, targeted therapies, and anti-VEGF therapy. In addition, a broad range of immuno-oncology agents can be combined to boost efficacy.
In squamous cell NSCLC, the practice-changing KEYNOTE-407 trial showed significantly increased overall survival (OS) with immunotherapy plus chemotherapy. The median OS was 15.9 months in the pembrolizumab group vs 11.3 months in the chemotherapy-alone group (HR 0.64; P=0.0008) [4].
According to Prof. Reck, efficacy was independent from PD-L1 status and there were no increases in immune-related adverse events (AEs) despite differences in the trial populations. OS outcomes were similar in phase 3 randomised trials of combination therapy for metastatic non-squamous cell NSCLC.
The KEYNOTE-189 trial reported an estimated OS rate of 69.2% in the pembrolizumab-combination group vs 49.4% in the placebo-combination group (HR 0.49; P<0.001) [5]. The IMpower150 trial found that adding atezolizumab to bevacizumab plus chemotherapy significantly improved OS (19.2 vs 14.7 months; HR 0.78; P=0.016). The outcome was independent from PD-L1 expression or EGFR or ALK genetic alteration [6].
Prof. Reck noted that while immunotherapy combinations benefit selected populations, convincing evidence for combining immunotherapy and targeted therapies has yet to be found. “AE rates have been unexpectedly high, but evaluation and clinical trials are ongoing,” he said. According to Prof. Reck, predictive markers are urgently needed to extend the benefits of combination therapies to more patients. Other issues being studied include the effects of sequencing on outcomes and the use of immunotherapy combinations as maintenance treatments.
- Paz-Ares L, et al. N Engl J Med 2018 Sep 25 [Epub ahead of print].
- Gandhi L, et al. N Engl J Med 2018;378:2078-2092.
- Socinski MA, et al. N Engl J Med 2018;378:2288-2301.
Posted on
Previous Article
« Spread through air spaces is prognostic in lung neuroendocrine tumours Next Article
Accumulation of concomitant mutations involved in drug resistance in sequential ALK TKI treatments of ALK-positive NSCLC »
« Spread through air spaces is prognostic in lung neuroendocrine tumours Next Article
Accumulation of concomitant mutations involved in drug resistance in sequential ALK TKI treatments of ALK-positive NSCLC »
Table of Contents: WCLC 2018
Featured articles
Interview with the IASCL President, Dr. Giorgio Scagliotti
Presidential Symposium – Top 5 abstracts
Durvalumab after chemoradiotherapy extends OS in stage 3, unresectable non-small-cell lung cancer
Potential for brigatinib as a first-line treatment option for ALK+ non-small-cell lung cancer
Benefits of chest CT screening
New standard of care in extensive-stage small-cell lung cancer
No progression-free survival benefit with nintedanib plus pemetrexed/cisplatin for malignant pleural mesothelioma of epithelial subtype
New Aspects of Immunotherapy
Next generation immunotherapy in non-small-cell lung cancer
Combination therapies: Where are we in 2018?
Choice of taxane and addition of pembrolizumab for metastatic squamous non-small-cell lung cancer
New Aspects of Targeted Therapy
PD-L1 expression in untreated EGFR-mutant non-small-cell lung cancer and response to osimertinib
Mesothelioma
Unmet needs in surgical management of malignant pleural mesothelioma
Advanced Non-small Cell Lung Cancer
Novel Therapies in ROS1 and EGFR
Advances in Small-cell and Neuroendocrine Tumours
Related Articles
November 21, 2018
Entrectinib treatment in patients with ROS1+ NSCLC
November 21, 2018
Spread through air spaces is prognostic in lung neuroendocrine tumours
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy